CD4 and neoplasm: These results suggest that BI-5756 does not affect T cell proliferation or viability but significantly upregulates Tregs and selectively suppresses CD4 and DP T cells by downregulating CD25 expression while preserving CD8 T cell activation, which potentially contributes to maintaining T cell-mediated anti-tumor response.